@article{90302032580048e8b1013b1478eaa96b,
title = "A longitudinal investigation of Aβ, anxiety, depression, and mild cognitive impairment",
abstract = "Introduction: We investigated the longitudinal relationship between cortical amyloid deposition, anxiety, and depression and the risk of incident mild cognitive impairment (MCI). Methods: We followed 1440 community-dwelling, cognitively unimpaired individuals aged ≥ 50 years for a median of 5.5 years. Clinical anxiety and depression were assessed using Beck Anxiety and Depression Inventories (BAI, BDI-II). Cortical amyloid beta (Aβ) was measured by Pittsburgh compound B positron emission tomography (PiB-PET) and elevated deposition (PiB+) was defined as standardized uptake value ratio ≥ 1.48. We calculated Cox proportional hazards models with age as the time scale, adjusted for sex, education, and medical comorbidity. Results: Cortical Aβ deposition (PiB+) independent of anxiety (BAI ≥ 10) or depression (BDI-II ≥ 13) increased the risk of MCI. There was a significant additive interaction between PiB+ and anxiety (joint effect hazard ratio 6.77; 95% confidence interval 3.58–12.79; P =.031) that is, being PiB+ and having anxiety further amplified the risk of MCI. Discussion: Anxiety modified the association between PiB+ and incident MCI.",
keywords = "Pittsburgh compound B positron emission tomography, amyloid imaging, anxiety, depression, mild cognitive impairment",
author = "Anna Pink and Janina Krell-Roesch and Syrjanen, {Jeremy A.} and Maria Vassilaki and Lowe, {Val J.} and Prashanthi Vemuri and Stokin, {Gorazd B.} and Christianson, {Teresa J.} and Kremers, {Walter K.} and Jack, {Clifford R.} and Knopman, {David S.} and Petersen, {Ronald C.} and Geda, {Yonas E.}",
note = "Funding Information: J.K.‐R. receives funding from the NIH and Roche. M.V. has received research funding from Roche and Biogen; currently consults for Roche; receives research funding from NIH; and has equity ownership in Abbott Laboratories, Johnson and Johnson, Medtronic, and Amgen. V.J.L. serves on scientific advisory boards for AVID Radiopharmaceuticals, Eisai Co. Inc., GE Healthcare, Bayer Schering Pharma, Piramal Life Sciences, and Merck Research, and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH. P.V. receives funding from the NIH. M.M.Mi. has consulted for Eli Lilly and Lysosomal Therapeutics, Inc. and receives unrestricted research grants from Biogen, and Lundbeck, and research funding from the NIH and the Department of Defense. W.K.K. receives research funding from the Department of Defense, the NIH, Astra Zeneca, Biogen, and Roche. C.R.J. serves on scientific advisory board for Eli Lilly, and IDSMB for Roche. But, he receives no compensation from any commercial entity. He receives research support from the NIH and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation. D.S.K. serves on a Data Safety Monitoring Board for the DIAN study. He is an investigator in clinical trials sponsored by Lilly Pharmaceuticals, Biogen, and the Alzheimer's Treatment and Research Institute at USC, and receives research support from the NIH. R.C.P. is a consultant for Roche, Biogen, Merck, Eli Lilly, and Genentech. He receives publishing royalties from (Oxford University Press, 2003) and research support from the NIH. Y.E.G. receives funding from the NIH and Roche, and served on Lundbeck Advisory Board. A.P., J.A.S., G.B.S., and T.J.C. report no disclosures. Mild Cognitive Impairment Funding Information: Support for this research was provided by NIH grants: National Institute on Aging (R01 AG057708; U01 AG006786; P50 AG016574; R01 AG034676; R01 AG011378; R01 AG041851), National Institute of Mental Health (K01 MH068351), and National Institute of Neurological Disorders and Stroke (R01 NS097495). This project was also supported by the Robert Wood Johnson Foundation, the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program, the GHR Foundation, the Mayo Foundation for Medical Education and Research, Project LQ1605 from the National Program of Sustainability II (MEYS CR), the Edli Foundation, and the Arizona Alzheimer's Consortium. Publisher Copyright: {\textcopyright} 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",
year = "2022",
month = oct,
doi = "10.1002/alz.12504",
language = "English (US)",
volume = "18",
pages = "1824--1831",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "10",
}